How many insider trades does FilingIQ track for INO?

FilingIQ tracks 441 Form 4 insider transactions for INO (INOVIO PHARMACEUTICALS, INC.), covering filings from Apr 13, 2015 onwards. 36 of those were filed in the last 90 days.

Are INO insiders net buyers or net sellers?

Across the full Form 4 history for INO, 13 transactions (3%) were open-market purchases and 72 (16%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does INO insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is INO in?

INOVIO PHARMACEUTICALS, INC. (INO) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $128.13M.

INO insider trading

NasdaqCM Healthcare

INOVIO PHARMACEUTICALS, INC. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

441

Last 90 days

Buys / sells

3% / 16%

Market cap

$128.13M

About INOVIO PHARMACEUTICALS, INC.

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the University of Pennsylvania, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Company website: www.inovio.com

INO insider activity at a glance

FilingIQ has scored 441 insider transactions for INO since Apr 13, 2015. The most recent filing in our index is dated Mar 31, 2026.

Across the full history, 13 open-market purchases and 72 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on INO insider trades is 55.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live INO trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for INO?: FilingIQ tracks 441 Form 4 insider transactions for INO (INOVIO PHARMACEUTICALS, INC.), covering filings from Apr 13, 2015 onwards. 36 of those were filed in the last 90 days.
Are INO insiders net buyers or net sellers?: Across the full Form 4 history for INO, 13 transactions (3%) were open-market purchases and 72 (16%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does INO insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is INO in?: INOVIO PHARMACEUTICALS, INC. (INO) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $128.13M.

Methodology & sources

Every INO insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.